Objective: To compare the efficacy and safety of dapagliflozin and dapagliflozin plus saxagliptin vs glimepiride as add-on to metformin in patients with type 2 diabetes.
| INTRODUCTION
Attainment of optimal glycaemic control with a low risk of hypoglycaemia and with body weight reduction is a major goal of type 2 diabetes management. 1, 2 Metformin is the first-line pharmacotherapy recommended for glycaemic control in patients with type 2 diabetes and has proven efficacy in achieving clinically relevant reduction in glycated haemoglobin (HbA1c) levels. 1 Most patients eventually require treatment with 2 or more antidiabetes agents to maintain adequate control of blood glucose levels, 3 and international treatment guidelines recommend stepwise intensification of therapy through add-on to metformin. 1, 4 The latest generation of oral antidiabetes drugs, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors, have demonstrated efficacy and safety in patients with inadequate glycaemic control with metformin monotherapy. [5] [6] [7] [8] [9] [10] Moreover, in a 24-week study, triple therapy with concomitant addition of dapagliflozin, an SGLT-2 inhibitor, plus the DPP-4 inhibitor saxagliptin to metformin led to greater improvements in glycaemic control than add-on of either agent alone. 11 These improvements were achieved without increased risk of hypoglycaemia compared with dual therapy, and both dapagliflozin-containing regimens were associated with the benefit of weight loss. 11 Dapagliflozincontaining treatment regimens, therefore, may be a promising secondline treatment strategy for patients with type 2 diabetes and inadequate glycaemic control.
Sulphonylureas are widely used as second-line therapy for type 2 diabetes. Although their efficacy as antidiabetes agents is established, drawbacks include hypoglycaemia, weight gain and limited long-term efficacy. Furthermore, data from some studies have suggested a possible association between sulphonylurea use and adverse cardiovascular outcomes. [12] [13] [14] Use of dapagliflozincontaining treatment regimens as second-line therapy may provide an alternative option to sulphonylureas, with a more favourable side-effect profile and additional beneficial effects on body weight and blood pressure control. In a head-to-head study, dapagliflozin and a sulphonylurea (glipizide) demonstrated similar efficacy, with the benefits of sustained reductions in body weight and systolic blood pressure (SBP), greater glycaemic durability and a lower rate of hypoglycaemia with dapagliflozin compared to glipizide after 1 year of treatment. 15 These effects continued to be observed in extensions of up to 4 years. [15] [16] [17] The primary aim of this study was to test the hypothesis that dapagliflozin, either alone or in combination with saxagliptin, is noninferior to titrated glimepiride, a sulphonylurea, in terms of glucoselowering effect in patients with type 2 diabetes who have inadequate glycaemic control with a maximum tolerated dose of metformin background therapy. Additional testing was undertaken to assess whether addition of dapagliflozin plus saxagliptin is superior to glimepiride plus metformin, given that triple therapy regimens have previously been
shown to be more efficacious than dual therapy. Other indicators of glycaemic control, metabolic parameters, body weight and blood pressure were assessed as secondary end points. severe congestive heart failure (New York Heart Association Class III and IV), decompensated or acute congestive heart failure, and/or left ventricular ejection fraction ≤40%.
| RESEARCH DESIGN AND METHODS

| Study design
| Treatments
The study design is shown in Figure 1 . Patients receiving metformin monotherapy were randomized (1:1:1) to 1 of 3 treatment arms by a computer-generated random sequence. These comprised dapagliflozin 10 mg; dapagliflozin 10 mg plus saxagliptin 5 mg; and glimepiride 0 to 6 mg (titrated). Matching placebos were used in each group and all study personnell were blinded to the randomization scheme during the study. Dapagliflozin and saxagliptin were taken orally, once daily, at fixed doses throughout the treatment period. Glimepiride treatment was initiated at 1 mg/day and was titrated upwards or downwards in 1 mg increments at subsequent visits, in accordance with prescribing information. The glimepiride/placebo dose was titrated to achieve an individualized FPG target, agreed by the patient and investigator at the start of treatment; a general target of approximately 110 mg/dL (6.1 mmol/L) was proposed in the study protocol. In order to reflect real-life clinical practice as closely as possible, glimepiride titration was allowed for the duration of the study.
In this study, hypoglycaemic events were categorized according 
| End points and assessments
The primary efficacy end point was absolute change in HbA1c from baseline to end of the 52-week treatment period. Key secondary end points included the proportion of patients reporting confirmed hypoglycaemic episodes during the 52-week treatment period, changes from baseline in total body weight and FPG at week 52, and the time to rescue during the treatment period. Additional secondary end points included the proportion of patients who achieved HbA1c < 7.0% at week 52, the proportion of patients who achieved ≥5% weight reduction, and the changes in waist circumference and in SBP at week 52. Safety end points included the incidence of adverse events (AEs) and hypoglycaemia, as well as findings from physical examinations, electrocardiograms (ECGs) and clinical laboratory evaluations.
| Statistical methods
The study was designed to demonstrate non-inferiority of dapagliflozin-containing treatment regimens relative to glimepiride in terms of the primary efficacy variable. Assuming no difference in dapagliflozin and dapagliflozin plus saxagliptin vs glimepiride with regard to HbA1c-lowering efficacy, as well as a standard deviation (SD) of 1.0, it was estimated that approximately 930 randomized patients would provide~95% power to demonstrate non-inferiority.
All efficacy analyses were conducted on the full analysis set (FAS), which comprised randomized patients who received at least 1 dose of study medication and for whom there were a baseline value and at least 1 post-baseline efficacy value. Analyses were performed using values prior to rescue treatment or discontinuation. The primary efficacy variable was analysed using a mixed-model repeated measures (MMRM) model with fixed effects for treatment group and covariates. Non-inferiority of dapagliflozin plus saxagliptin to glimepiride was assessed first, followed by non-inferiority of dapagliflozin alone to glimepiride, based on a prespecified margin of 0.3%. Superiority of dapagliflozin plus saxagliptin to glimepiride was also assessed. Sensitivity analysis was conducted for the primary end point by repeating the primary efficacy analysis using data from the per protocol set, which comprised patients in the FAS who did not have relevant protocol deviations.
Analyses of secondary efficacy variables (change from baseline in body weight and FPG) were performed using an MMRM model similar to that used for the primary end point. The proportion of patients with confirmed hypoglycaemia was analysed using Fisher's exact test and time to rescue was analysed using a Cox proportional hazards model. Statistical comparisons were performed using a comparison-wise type 1 error of 5% (two-sided). To control the overall type 1 error of the study, a hierarchical closed testing procedure was employed: if non-inferiority of the primary end point was demostrated, testing was performed for key secondary efficacy variables according to the sequential order pre-specified in the study protocol. Any given key secondary end point was considered for significance only if the key secondary end point before it demonstrated statistical significance.
For other secondary variables and exploratory variables, nominal P values were reported without significance testing.
Safety analyses were performed on the safety analysis set, which comprised patients who received at least 1 dose of study medication, regardless of rescue treatment; safety data were summarized using descriptive statistics. Baseline demographics and diabetes characteristics (Table 1) 
| RESULTS
| Patient disposition and characteristics
| Study drug treatment
The mean (SD) titrated glimepiride dose at Week 52 was 4.6 (1.8) mg;
the maximum dose was 6 mg for 164 patients (52.6%) and 7.7% of patients were receiving 1 mg at Week 52. The glimepiride dose was down-titrated to 0 mg in the case of four patients (1.3%).
| Efficacy 3.3.1 | Primary efficacy end point
Adjusted mean change from baseline in HbA1c at 52 weeks was −0.82% for dapagliflozin alone and −1.20% for dapagliflozin plus saxagliptin, compared with −0.99% for glimepiride when added to baseline metformin monotherapy (Table 2 and Figure 2A ). Non-inferiority, based on a prespecified margin of 0.3%, was demonstrated for both dapagliflozin-containing treatment groups, relative to glimepiride, at Week 52. The change in HbA1c from baseline was statistically significantly greater (P = 0.001) with dapagliflozin plus saxagliptin than with glimepiride, thereby demonstrating superiority of dual add-on (triple therapy) over glimepiride plus metformin. Figure 2B shows adjusted mean changes from baseline in HbA1c over the 52-week treatment period. The major benefits of treatment, in terms of HbA1c reduction, were achieved within the first 12 weeks in all treatment arms.
| Secondary end points
The proportion of patients experiencing at least one episode of confirmed hypoglycaemia during the 52-week treatment period was low across all groups (<5%) and was significantly lower in both dapagliflozin-containing treatment groups than in the glimepiride group (Table 2) . Total body weight decreased from baseline to Week 52 in both dapagliflozin-containing treatment groups, whereas it increased in the glimepiride group (Table 2) . Reductions in FPG from baseline to Week 52 were statistically significantly greater with dapagliflozin plus saxagliptin than with glimepiride as add-on therapy, and dapagliflozin was non-inferior to glimepiride as add-on therapy (Table 2 ). The time courses to onset of changes in FPG and body weight were similar to those for HbA1c, in that the majority of the treatment effect was achieved by Week 12 with both dapagliflozincontaining treatment regimens ( Figure S1 ). The number of patients (proportions) who met rescue criteria during the treatment period were 58 (18.6%), 26 (8.3%) and 66 (21.4%) in the dapagliflozin, dapagliflozin plus saxagliptin and glimepiride add-on to metformin groups, respectively ( Table 2 ).
The proportion of patients who achieved HbA1c < 7.0% at Week 52, regardless of hypoglycaemia, was greater with add-on dapagliflozin plus saxagliptin than with add-on glimepiride ( Table 2 ). The proportion of patients with a weight reduction of ≥5% from baseline to Week 52 was higher in the dapagliflozin and dapagliflozin plus saxagliptin groups compared with the glimepiride group ( Table 2) . Mean waist circumference decreased with dapagliflozin-containing regimens, whereas it increased with glimepiride (Table 2) . Moreover, there were greater reductions in SBP from baseline to Week 52 with dapagliflozin and dapagliflozin plus saxagliptin add-on therapies than with glimepiride (Table 2 and Figure S2 ).
| Hypoglycaemia
The overall incidence of hypoglycaemia was substantially lower with dapagliflozin-containing treatment regimens than with glimepiride add-on to metformin. In total, there were 10, 19 and 329 hypoglycaemic events with add-on dapagliflozin, dapagliflozin plus saxagliptin and glimepiride, respectively (Table 3) . Notably, no episodes of major hypoglycaemia occurred in any treatment group and there was little difference in the incidence of hypoglycaemia prior to and after rescue.
The distribution of hypoglycaemic events over time is shown in Figure S2 .
| Safety and tolerability
Overall, the proportion of patients reporting an AE was similar between treatment groups (range, 50.6%-60.1%) ( Table 3 ). In the add-on dapagliflozin, add-on dapagliflozin plus saxagliptin and add-on glimepiride groups, UTIs were reported by 24 (7.7%), 13 (4.2%) and 12 (3.8%) patients, respectively. These events were all mild or moderate in severity. Genital infections were reported in 25 (8.0%), 15 (4.8%) and 2 (0.6%) patients in the dapagliflozin, dapagliflozin plus saxagliptin and glimepiride add-on therapy groups, respectively. In the add-on dapagliflozin plus saxagliptin group, one patient experienced an event of increased blood ketone body concentration. The event was mild in intensity and pH values during the event were reported to be within the normal range; the patient did not discontinue study medication.
A total of 52 AEs led to discontinuation of study treatment. These events occurred in 27 (8.6%), 12 (3.8%) and 13 (4.2%) patients in the dapagliflozin, dapagliflozin plus saxagliptin and glimepiride groups, respectively (Table 3) . Serious AEs (SAEs) were reported in 39 (12.5%), 22 (7.1%) and 35 (11.2%) patients in the dapagliflozin, dapagliflozin plus saxagliptin and glimepiride groups, respectively. One SAE (UTI) in the add-on dapagliflozin group was considered by the investigator to be related to the study treatment. SAEs leading to study drug discontinuation were dispersed across multiple system organ classes and included renal, urinary and cardiac disorders. These events were reported by 13 (4.2%) and 3 (1.0%) patients in the addon dapagliflozin and add-on glimepiride groups, respectively. No SAEs leading to study drug discontinuation occurred in the dapagliflozin plus saxagliptin group. 
| DISCUSSION
This study evaluated the efficacy and safety of add-on therapy with dapagliflozin vs glimepiride in metformin-treated patients with type 2 diabetes who had inadequate glycaemic control. We considered two regimens: either dapagliflozin alone or in combination with saxagliptin, as a combination of an SGLT-2 and a DPP-4 inhibitor has been shown previously to lead to superior improvements in glycaemic control than that achieved with either agent alone.
For the primary end point of change from baseline in HbA1c at
Week 52, non-inferiority was demonstrated for the combination of dapagliflozin and metformin compared with glimepiride plus metformin. Superiority was met for this end point for triple therapy with dapagliflozin, saxagliptin and metformin vs glimepiride plus metformin.
Similar trends were observed for key secondary end points; with dapagliflozin-containing regimens, superiority was met for the proportion of patients reporting confirmed hypoglycaemic episodes during treatment, as well as for the change from baseline in total body weight at Week 52. Both dapagliflozin-containing regimens decreased FPG from baseline to Week 52 to an equal or greater extent than glimepiride plus metformin. All treatment regimens were well tolerated, and the safety profile of the dapagliflozin-saxagliptin combination was in line with that of the individual drugs, without additional side effects.
Findings from this study are in accordance with those from previous studies of dapagliflozin and saxagliptin when administered as part of either dual or triple therapy with metformin. 6, 7, 11, 18 The results were also in line with previous head-to-head comparisons of dapagliflozin and other SGLT-2 inhibitors vs sulphonylureas. [15] [16] [17] 19, 20 In this study, dapagliflozin-containing treatment regimens were associated with the additional benefit of weight loss, compared with glimepiride therapy which was associated with weight gain during treatment. Over 20% of patients in both dapagliflozin treatment groups achieved ≥5% weight loss, compared with only 3.5% of patients in the add-on glimepiride group. This is of importance, given that body weight reduction is a key treatment goal in patients with type 2 diabetes. 1 Dapagliflozin-containing regimens also reduced SBP, an effect that has been observed previously with SGLT-2 inhibitor treatment 21, 22 and might be attributable to the osmotic, natriuretic and weight-reducing effects of these agents. 23, 24 This is likely to be beneficial to patients with type 2 diabetes, given that achievement of blood pressure targets is associated with reduced risk of microvascular and macrovascular diabetes complications, including cardiovascular disease. 25 Dapagliflozin-containing treatment regimens were well tolerated during the study. Although there were more UTIs and genital infections in the dapagliflozin groups than in the glimepiride group, these were all mild or moderate in intensity and the frequency was consistent with previous reports. 11, 26, 27 In line with some previous reports, the frequency of both types of infection was lower in the dapagliflozin plus saxagliptin combination arm compared with the dapagliflozin arm.
Several hypotheses for the mechanism underlying this phenomenon have been proposed, the simplest being that addition of a DPP-4 inhibitor augments overall glucose control and thereby reduces SGLT-2 inhibitor-mediated glucosuria. 28 However, there are arguments that challenge this hypothesis and dedicated experimental studies are required to provide greater clarity.
Treatment with SGLT-2 inhibitors has been associated with transient reductions in eGFR. More patients receiving dapagliflozin plus metformin experienced decreased CrCl leading to study discontinuation than did patients receiving glimepiride (2.9% vs 1.3%) However, the study criterion for discontinuation because of decreased CrCl was strict and did not allow CrCl to decrease below 60 mL/min if not reversed within 1 week of detection. Previous studies have shown that the initial effect of SGLT-2 inhibitors on renal filtration is reversible and is associated with beneficial effects such as reduced albumin excretion and protection of renal function in patients with micro-and macroalbuminuria. [29] [30] [31] [32] An important adverse effect of sulphonylureas is the invariable induction of hypoglycaemia, which is associated with numerous Abbreviations: CI, confidence interval; DAPA, dapagliflozin; FAS, full analysis set; FPG, fasting plasma glucose; GLIM, glimepiride; HbA1c, glycated haemoglobin; MET, metformin; MMRM, mixed-model repeated measures; SAXA, saxagliptin; SD, standard deviation; SE, standard error.
a P values for non-inferiority were not calculated; non-inferiority was assessed using the two-sided 95% CI of the adjusted mean difference between dapagliflozin or dapagliflozin plus saxagliptin and glimepiride, using a prespecified margin of 0.3%. e Cox proportional hazards model with term for treatment. The Efron method was used in cases where patients had identical rescue times. Time to rescue treatment is censored at the earliest occurrence of the following: discontinuation of study medication, study completion or time of insulin initiation.
detrimental patient outcomes. 33 In this study, there were substantially fewer hypoglycaemic episodes in patients taking dapagliflozin-containing regimens than in patients receiving glimepiride plus metformin. This is consistent with findings from a previous study 16 and with the mechanism of action of dapagliflozin, which does not depend on insu- access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. f Asymptomatic hypoglycaemia: event with absence of symptoms but with glucose ≤3.9 mmol/L (≤70 mg/dL).
